49.9% once Todos uplists. (Could be more like m
Post# of 30067
(Total Views: 435)
Posted On: 10/15/2019 3:00:00 PM
49.9% once Todos uplists.
(Could be more like mid 40% after all is said and done most likely. We have to wait and see how everything plays out.)
Todos Medical Exercises Option to Acquire Remaining 80.01% of Breakthrough Diagnostics from Amarantus After Review of Alzheimer's Blood Test Data
REHOVOT, Israel, May 28, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced that it has received and analyzed data from the University of Leipzig on the lymphocyte proliferation test (‘LymPro”), which demonstrated a strong correlation between LymPro and amyloid PET. Upon review of the LymPro data, Todos Medical exercised its exclusive option to acquire the remaining 80.01% of its joint venture Breakthrough Diagnostics from Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS). The transaction is expected to close upon listing of Todos’ common stock on a national stock exchange.
http://investor.todosmedical.com/news-release...ining-8001
(2) The approval of a change of control transaction with Amarantus Bioscience Holdings, Inc. (“Amarantus”), currently a 19.99% shareholder of the Company, whereby the Company will issue to Amarantus an additional thirty percent (30%) of the Company in exchange for obtaining Amarantus’s 80.01% ownership stake in our jointly-owned subsidiary Breakthrough Diagnostics, Inc. (“Breakthrough”), such that upon consummation of the transaction the Company will own 100% of Breakthrough and Amarantus will own 49.99% of the Company;
https://investorshangout.com/post/view?id=542...z62RvroREg
Aloha
(Could be more like mid 40% after all is said and done most likely. We have to wait and see how everything plays out.)
Todos Medical Exercises Option to Acquire Remaining 80.01% of Breakthrough Diagnostics from Amarantus After Review of Alzheimer's Blood Test Data
REHOVOT, Israel, May 28, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced that it has received and analyzed data from the University of Leipzig on the lymphocyte proliferation test (‘LymPro”), which demonstrated a strong correlation between LymPro and amyloid PET. Upon review of the LymPro data, Todos Medical exercised its exclusive option to acquire the remaining 80.01% of its joint venture Breakthrough Diagnostics from Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS). The transaction is expected to close upon listing of Todos’ common stock on a national stock exchange.
http://investor.todosmedical.com/news-release...ining-8001
(2) The approval of a change of control transaction with Amarantus Bioscience Holdings, Inc. (“Amarantus”), currently a 19.99% shareholder of the Company, whereby the Company will issue to Amarantus an additional thirty percent (30%) of the Company in exchange for obtaining Amarantus’s 80.01% ownership stake in our jointly-owned subsidiary Breakthrough Diagnostics, Inc. (“Breakthrough”), such that upon consummation of the transaction the Company will own 100% of Breakthrough and Amarantus will own 49.99% of the Company;
https://investorshangout.com/post/view?id=542...z62RvroREg
Aloha
(4)
(0)